After an efficient process, Hemcheck has CE-marked its products for diagnostic purposes. This strengthens the sales and profitability potential as it enables sales to new segments and at clearly higher price levels than today.
– There is a lot of work behind the CE marking and I am very happy that we have been able to carry out this project in such an efficient way. This opens up additional segments and the sales potential within these can, depending on assumptions, amount to hundreds of millions of SEK globally. We have already carried out and have ongoing user tests as well as a clear interest from customers in these segments. The sales and marketing efforts can now be initiated and we hope for a positive development, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.